A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Loading...
Identifiers
Publication date
2023
Start date of the public exhibition period
End date of the public exhibition period
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
OncoImmunology
Share
Abstract
Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range
of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to
increase the ICB response rates are urgently needed. New bispecific antibody (bsAb) formats combining
the ICB effect and a direct action on cancer cells could improve the efficacy of current immunotherapies.
Here, we report the development of a PD-L1/EGFR symmetric bsAb by fusing a dual-targeting tandem
trimmer body with the human IgG1 hinge and Fc regions. The bsAb was characterized in vitro and the
antitumor efficacy was evaluated in humanized mice bearing xenografts of aggressive triple-negative
breast cancer and lung cancer. The IgG-like hexavalent bsAb, designated IgTT-1E, was able to simultaneously bind both EGFR and PD-L1 antigens, inhibit EGF-mediated proliferation, effectively block PD-1/PD-L1 interaction, and induce strong antigen-specific antibody-dependent cellular cytotoxicity activity in vitro. Potent therapeutic efficacies of IgTT-1E in two different humanized mouse models were observed, where tumor growth control was associated with a significantly increased proportion of CD8+ T cells. These results support the development of IgTT-1E for the treatment of EGFR+ cancers.
Doctoral program
Description
Keywords
Cancer immunotherapy, bispecific antibody, Dual action, Epithelial growth factor receptor, Immune checkpoint blockade